You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PF-02341066

Showing 1 - 25 of 1,106
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Feb 4, 2022

Advanced Cancers Trial in Houston (Crizotinib, Dasatinib)

Completed
  • Advanced Cancers
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jun 29, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial in Houston (Axitinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2021

NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)

Completed
Has Results
  • Non-Small Cell Lung Cancer ALK-positive
  • +4 more
  • PF-02341066
  • +2 more
  • Orange, California
  • +28 more
Feb 15, 2022

Castration-resistant Prostate Cancer Trial in Boston (Crizotinib, Enzalutamide)

Completed
  • Castration-resistant Prostate Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 5, 2022

Tumors Malignant Trial in Worldwide (Crizotinib)

Active, not recruiting
  • Neoplasms Malignant
  • Fayetteville, Arkansas
  • +20 more
Oct 5, 2021

Solid Tumor, Colorectal Cancer Trial in Oxford (PF-02341066, PD-0325901, Binimetinib)

Completed
Has Results
  • Solid Tumor
  • Colorectal Cancer
  • PF-02341066
  • +2 more
  • Oxford, United Kingdom
    Oxford University Hospital NHS Trust
Jun 14, 2021

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory

Active, not recruiting
  • Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma
  • +5 more
  • Crizotinib (PF-02341066)
  • Brussels, Belgium
  • +24 more
May 9, 2022

Advanced Cancers Trial in Houston (Crizotinib (Xalkori), Pazopanib, Pemetrexed)

Terminated
  • Advanced Cancers
  • Crizotinib (Xalkori)
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 3, 2021

Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

Completed
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2021

NSCLC Trial in Worldwide (Avelumab, PF-06463922, Crizotinib)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Atlanta, Georgia
  • +20 more
Jan 13, 2022

Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell Trial run by the NCI (PF-02341066/PF-00299804)

Terminated
  • Carcinoma, Non-Small Cell Lung
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 14, 2019

Advanced Solid Tumors Trial in United Kingdom, United States (axitinib, crizotinib)

Completed
Has Results
  • Advanced Solid Tumors
  • Chicago, Illinois
  • +16 more
Sep 1, 2020

Solid Tumors Trial in Worldwide (axitinib, crizotinib)

Active, not recruiting
  • Solid Tumors
  • Orange, California
  • +33 more
Jan 30, 2021

Diffuse Intrinsic Pontine Glioma, High-grade Glioma Trial in Memphis (Crizotinib, Dasatinib)

Completed
  • Diffuse Intrinsic Pontine Glioma
  • High-grade Glioma
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Mar 20, 2019

Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent NSCLC Trial in United States (crizotinib, pemetrexed disodium,

Terminated
Has Results
  • Adenocarcinoma of the Lung
  • +3 more
  • Sacramento, California
  • +166 more
Feb 19, 2020

Healthy Participants Trial (Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet

Not yet recruiting
  • Healthy Participants
  • Single dose of PF-07220060 as first Tablet Formulation
  • +3 more
  • (no location specified)
Jun 20, 2023

Atopic Dermatitis Trial in United States (PF-07275315, PF-07264660, Placebo)

Not yet recruiting
  • Atopic Dermatitis
  • Huntington Beach, California
  • +3 more
Aug 21, 2023

Healthy Trial (PF-07976016, Placebo, Midazolam)

Not yet recruiting
  • Healthy
  • (no location specified)
Oct 24, 2023

Hemiparesis;Poststroke/CVA Trial in Créteil (Eccentric training, Conventional therapy)

Recruiting
  • Hemiparesis;Poststroke/CVA
  • Eccentric training
  • Conventional therapy
  • Créteil, France
    Wael Maktouf
Nov 16, 2023

Healthy Trial in New Haven, Brussels (PF-07817883, Placebo, Midazolam)

Recruiting
  • Healthy
  • New Haven, Connecticut
  • +1 more
Dec 19, 2022

Pulmonary Arterial Hypertension Trial (PF-07868489, Placebo for PF-07868489)

Not yet recruiting
  • Pulmonary Arterial Hypertension
  • (no location specified)
Nov 14, 2023

Breast Cancer, Ovarian Cancer, Liposarcoma Trial (PF-07224826, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • +5 more
  • (no location specified)
Jun 7, 2023

Hemolysis During Pulsed-field and Radiofrequency Ablation

Not yet recruiting
  • Atrial Fibrillation
  • +2 more
  • Pulsed-field ablation
  • Radiofrequency ablation
  • Prague, Czechia
    Cardiocenter, 3rd Medical School, Charles University and Univers
Oct 20, 2023

Healthy Trial in New Haven (PF-07328948, Placebo)

Recruiting
  • Healthy
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Jan 5, 2023